{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T11:56:26Z","timestamp":1770724586679,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.cllc.2015.12.006","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T14:51:30Z","timestamp":1450450290000},"page":"128-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former\/Light Smoking Patients With Stage IV Non\u2013Small Cell Lung Cancer"],"prefix":"10.1016","volume":"17","author":[{"given":"Jared M.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza C.","family":"Villaruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathon","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anastasia","family":"Ivanova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4786-3834","authenticated-orcid":false,"given":"Carrie","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juneko Grilley","family":"Olson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory","family":"Pollack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Gorman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Socinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas E.","family":"Stinchombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2015.12.006_bib1","doi-asserted-by":"crossref","first-page":"5622","DOI":"10.1158\/1078-0432.CCR-09-0373","article-title":"Lung cancer in never smokers: a call to action","volume":"15","author":"Rudin","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cllc.2015.12.006_bib2","first-page":"69","article-title":"Global cancer statistics","volume":"61","author":"Jemal","year":"2011","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.cllc.2015.12.006_bib3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/cncr.24813","article-title":"Pack-years of cigarette smoking as a prognostic factor in patients with stage IIIB\/IV nonsmall cell lung cancer","volume":"116","author":"Janjigian","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2015.12.006_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1378\/chest.126.2.347","article-title":"Improved survival in never-smokers vs current smokers with primary adenocarcinoma of the lung","volume":"126","author":"Nordquist","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.cllc.2015.12.006_bib5","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1200\/JCO.2005.04.8033","article-title":"Never-smokers with lung cancer: epidemiologic evidence of a distinct disease entity","volume":"24","author":"Toh","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib6","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1002\/cncr.21884","article-title":"Smoking affects treatment outcome in patients with advanced nonsmall cell lung cancer","volume":"106","author":"Tsao","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.cllc.2015.12.006_bib7","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0169-5002(03)00038-2","article-title":"Survival among Chinese women with lung cancer in Singapore: a comparison by stage, histology and smoking status","volume":"40","author":"Tan","year":"2003","journal-title":"Lung Cancer"},{"key":"10.1016\/j.cllc.2015.12.006_bib8","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib9","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/JTO.0b013e318160c607","article-title":"Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma","volume":"3","author":"Marks","year":"2008","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib10","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1200\/JCO.2004.08.158","article-title":"Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Miller","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib11","doi-asserted-by":"crossref","first-page":"7435","DOI":"10.1038\/sj.onc.1205803","article-title":"Tobacco smoke carcinogens, DNA damage and p53 mutations in smoking-associated cancers","volume":"21","author":"Pfeifer","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.cllc.2015.12.006_bib12","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2015.12.006_bib13","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1200\/JCO.2008.20.8181","article-title":"Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer","volume":"27","author":"Patel","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib14","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1200\/JCO.2011.40.1315","article-title":"Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial","volume":"30","author":"Janne","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib15","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMoa0810699","article-title":"Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma","volume":"361","author":"Mok","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cllc.2015.12.006_bib16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.cllc.2015.12.006_bib17","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1200\/JCO.2012.47.9626","volume":"31","author":"Patel","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib18","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1200\/JCO.2012.42.3749","article-title":"Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089)","volume":"31","author":"Barlesi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib19","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib20","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1097\/JTO.0b013e3182208ea8","article-title":"Significance of thymidylate synthase and thyroid transcription factor 1 expression in patients with nonsquamous non-small cell lung cancer treated with pemetrexed-based chemotherapy","volume":"6","author":"Sun","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib21","doi-asserted-by":"crossref","first-page":"e74284","DOI":"10.1371\/journal.pone.0074284","article-title":"Association between TYMS expression and efficacy of pemetrexed-based chemotherapy in advanced non-small cell lung cancer: a meta-analysis","volume":"8","author":"Wang","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.cllc.2015.12.006_bib22","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mds590","article-title":"Systematic review and meta-analysis of randomised, phase II\/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer","volume":"24","author":"Soria","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib23","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1200\/JCO.2009.25.4482","article-title":"Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599","volume":"28","author":"Dahlberg","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib24","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/S0140-6736(11)60545-X","article-title":"Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial","volume":"377","author":"Herbst","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cllc.2015.12.006_bib25","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/S1470-2045(14)70381-X","article-title":"Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study","volume":"15","author":"Seto","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib26","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1097\/JTO.0b013e31820cf053","article-title":"Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed","volume":"6","author":"Camidge","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib27","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1097\/JTO.0b013e3182208fc2","article-title":"Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer","volume":"6","author":"Lee","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib28","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/annonc\/mds242","article-title":"Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer","volume":"24","author":"Shaw","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cllc.2015.12.006_bib29","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1097\/JTO.0b013e3181f7c6d4","article-title":"Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer","volume":"6","author":"Scagliotti","year":"2011","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730415003009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730415003009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:05:06Z","timestamp":1761505506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730415003009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S1525730415003009"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2015.12.006","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Results of a Phase II Trial of Carboplatin, Pemetrexed, and Bevacizumab for the Treatment of Never or Former\/Light Smoking Patients With Stage IV Non\u2013Small Cell Lung Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2015.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}